AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04124627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance in addition to radiographic guidance
Description: Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
Study NCT03001843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pain scale
Description: 0-10 pain scale. 0 = no pain and 10 = worst pain
Study NCT02205502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
Study NCT02205502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT03858218 — intervention group
Intervention type: OTHER
Intervention: questionnaires set
Description: questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
Study NCT03218891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation.
Study NCT01564459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
Study NCT01564459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-6096
Description: MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
Study NCT01564459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching compressed tablets, taken once daily at bedtime for 14 days.
Study NCT02818387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
Study NCT02818387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
Study NCT01488942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monetary reinforcer
Description: The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
Study NCT01313520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
Study NCT01313520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
Study NCT02749877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: (Training Details already described above)
Study NCT02749877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory Training
Description: (Training Details already described above)
Study NCT02749877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: (Training Details already described above)
Study NCT02749877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training
Description: (Training Details already described above)
Study NCT02679378 — intervention group
Intervention type: DEVICE
Intervention: ClearSight™ System
Description: comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
Study NCT02912728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CGM + Family Behavioral Intervention
Description: use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
Study NCT02912728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CGM
Description: use of CGM alone to assess CGM adherence
Study NCT05152017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M Quadro [inactivated split influenza vaccine] with preservative
Description: solution for intramuscular injection, 0.5 ml
Study NCT05152017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M Quadro [inactivated split influenza vaccine] without preservative
Description: solution for intramuscular injection, 0.5 ml
Study NCT05152017 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for intramuscular injection, 0.5 ml
Study NCT00523341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months.
Study NCT00857753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl patch 25 ug/nr Sandoz
Study NCT00857753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragesic
Study NCT03327181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: short chain fatty acid tracers
Description: stable tracer infusion of acetate, propionate, and butyrate
Study NCT03327181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: short chain fatty acid tracers
Description: stable tracer infusion of acetate, propionate, and butyrate
Study NCT01833104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presence - Perspective - Affect
Description: PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad.
Study NCT01833104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presence - Affect - Perspective.
Description: As specified above however the order is interchanged between the cohorts TC1 and TC2.
Study NCT01833104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect
Description: AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad.
Study NCT00796094 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
Study NCT04895605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS Laser
Description: The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
Study NCT04895605 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
Study NCT04382898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT112
Description: Intravenous bolus injection
Study NCT04382898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous infusion
Study NCT00296361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: immunosuppression
Study NCT03452189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Oral vancomycin 250mg capsules
Study NCT03452189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: Oral vancomycin 250mg capsules
Study NCT03452189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo Pills distributed by Research Pharmacy labeled placebo.
Study NCT03452189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Pills distributed by Research Pharmacy labeled placebo.
Study NCT03200626 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous hematopoietic cell transplant
Description: Autologous hematopoietic cell transplant
Study NCT04898140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 specific IgM and IgG detection
Description: Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
Study NCT04898140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins
Description: Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
Study NCT04898140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes
Description: Detection of peripheral blood T-helpers (CD45+CD3+CD4+)\* and cytotoxic T cells (CD45+CD3+CD8+)\* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. \* CD, cluster of differentiation
Study NCT00232349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
Study NCT03344536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
Study NCT03344536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1347
Description: Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
Study NCT02818387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
Study NCT01117337 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Mesh Fixation
Description: Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Subjects will receive tacrolimus once daily on Day 1 and Day 24
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Subjects will receive dabigatran once daily on Day 1 and Day 13
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin once daily on Day 1 and Day 13
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
Study NCT04498741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive midazolam once daily on Day 1 and Day 16
Study NCT04054128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 7.5% Injection
Description: Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
Study NCT04054128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium, 1000 Units/mL Injectable Solution 1
Description: Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
Study NCT00705692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole
Study NCT00705692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00257920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar® injection
Description: 6 mcg QOD
Study NCT00257920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hectorol® injection
Description: 3.6 mcg QOD
Study NCT01261741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Each subject will receive memantine 10mg tablets once daily
Study NCT01261741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will receive matching placebo tablets once daily
Study NCT00578071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
Study NCT00578071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
Study NCT00578071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
Study NCT00578071 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Daily for 6 weeks
Study NCT01507974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive antibiotic treatment- NITROFURANTOIN
Description: P.O NITROFURANTOIN 100 mg per day for 6 weeks
Study NCT01507974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive antibiotic treatment- CEPHALEXIN
Description: P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
Study NCT01507974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT- AMOXICILLIN
Description: P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
Study NCT01507974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM
Description: P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
Study NCT01507974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT- CEFUROXIME
Description: P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
Study NCT01507974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM
Description: P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
Study NCT04247984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered on day 1 of a 2-week cycle.
Study NCT04247984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered on day 1 of a 2-week cycle.
Study NCT04247984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
Study NCT04247984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
Study NCT03454529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03454529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study NCT01456013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard Therapy
Description: Induced Diuresis with matched replacement
Study NCT04173442 — intervention group
Intervention type: DRUG
Intervention: dupilumab
Description: Dupilumab cohort
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 5 mg
Description: BIA 9-1067 OPC, Opicapone 5 mg
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone 200 mg
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (four times a day)
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (four times a day)
Study NCT04247984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
Study NCT04247984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CF
Description: 300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
Study NCT04247984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
Study NCT02307643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303 Low dose
Study NCT02307643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303 High dose
Study NCT04346966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
Study NCT01764243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4666
Description: low dose, high dose
Study NCT01764243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00871741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: Intramuscular, three doses
Study NCT00871741 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular, three doses
Study NCT00871741 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: Intramuscular, two doses
Study NCT00663832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 (i.v. panobinostat)
Description: i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle
Study NCT03119506 — intervention group
Intervention type: BEHAVIORAL
Intervention: Recess
Description: Recess timing and duration effects on lunch intake